Breaking News Instant updates and real-time market news.

NTEC

Intec Pharma

$7.05

0.2 (2.92%)

, NVS

Novartis

$86.27

0.85 (1.00%)

08:15
01/08/18
01/08
08:15
01/08/18
08:15

Intec Pharma enters Feasibility and Option agreement with Novartis

Intec Pharma (NTEC) announced it has entered into a Feasibility and Option agreement with Novartis Pharmaceuticals (NVS) to explore using the Accordion Pill platform for a proprietary Novartis compound. The details of the therapeutic area or specific compound were not released. Following potentially successful feasibility studies including a Phase 1 PK study, Novartis has the option to enter into negotiations with respect to a potential licensing agreement for employing Intec Pharma Accordion Pill technology.

NTEC

Intec Pharma

$7.05

0.2 (2.92%)

NVS

Novartis

$86.27

0.85 (1.00%)

  • 08

    Jan

  • 08

    Jan

  • 18

    Jan

  • 08

    Feb

  • 16

    Feb

  • 17

    May

NTEC Intec Pharma
$7.05

0.2 (2.92%)

09/21/17
OPCO
09/21/17
NO CHANGE
Target $15
OPCO
Outperform
Intec Pharma price target raised to $15 from $10 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Intec Pharma to $15 from $10 as he is optimistic about the prospects for its clinical assets which rely on the Accordion Pill platform, namely AP-CD/LD for Parkinson's disease and AP-CBD/THC for chronic pain. The analyst reiterates an Outperform rating on the shares.
10/13/17
OPCO
10/13/17
NO CHANGE
Target $15
OPCO
Outperform
Opco more optimistic on Intec Pharma after meeting management
Oppenheimer analyst Jay Olson is "incrementally more optimistic" in his outlook for Intec Pharma after meeting with management. The analyst is "encouraged" by new CEO Jeff Meckler's vision for the Accordion Pill as a platform to unlock significant value for shareholders beyond the current opportunity in Parkinson's disease. Olson maintains an Outperform rating on Intec with a $15 price target.
NVS Novartis
$86.27

0.85 (1.00%)

12/01/17
WELS
12/01/17
NO CHANGE
Target $1525
WELS
Outperform
Amazon price target raised to $1,525 from $1,430 at Wells Fargo
Wells Fargo analyst Ken Sena raised his price target for Amazon.com (AMZN) to $1,525 to reflect increased outer-year estimates for Web Services as well as a higher sum-of-the-parts valuation. The stock closed yesterday up $15.48 to $1,176.75. The analyst highlights the "very successful" five-day Amazon Wed Services conference in Las Vegas, "record-breaking" early holiday sales data, and another healthcare industry development with CNBC reporting the company is in talks with generic manufacturers Mylan (MYL) and Novartis (NVS). Sena sees an increasing likelihood that Amazon "ultimately becomes a disruptor" in healthcare, with generics representing a potential point of entry. The Wells Fargo Healthcare team sees generics as a "simple entry point" in pharma as it involves many players with ready supply and a price competitive market, Sena tells investors in a research note. The analyst keeps an Outperform rating on Amazon.
12/06/17
BOFA
12/06/17
DOWNGRADE
BOFA
Underperform
Novartis downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Graham Perry downgraded Novartis to Underperform citing recent share strength, Cosentyx competition, and lack of catalysts.
12/13/17
PIPR
12/13/17
NO CHANGE
PIPR
Overweight
Piper calls Regeneron 'essential name to own' in 2018
After spending time with management, Piper Jaffray analyst Christopher Raymond calls Regeneron Pharmaceuticals (REGN) an "essential name to own" in 2018. The analyst believes next year is setting up well for the stock with a "steady stream of meaningful data" and what he expects will be "solid operational upside." The rumors of Eylea's demise are greatly exaggerated, Raymond tells investors in a research note. He notes that management expressed confidence that Eylea's regimen will remain superior to retinal specialists versus Novartis' (NVS) RTH258. Raymond remains a buyer of Regeneron with an Overweight rating and $540 price target. The stock in afternoon trading is up 2%, or $7.78, to $389.50.
01/05/18
NEED
01/05/18
INITIATION
Target $65
NEED
Buy
Juno Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Juno Therapeutics (JUNO) with a Buy rating and a price target of $65. Messer says that while Novartis (NVS) and Gilead (GILD) have reached the CAR-T technology market ahead of Juno, the latter is "developing safer and potentially better products", positioning itself with "best-in-class technology". The analyst believes that the selloff in the stock price since the December ASH conference creates an attractive near-term entry point for investors.

TODAY'S FREE FLY STORIES

UAL

United Continental

$77.97

1.11 (1.44%)

16:55
01/23/18
01/23
16:55
01/23/18
16:55
Hot Stocks
United Continental says mid-continent hubs account for margin underperformance »

Says mid-continent hubs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

16:55
01/23/18
01/23
16:55
01/23/18
16:55
Conference/Events
CFA Society of Columbus to hold a dinner meeting »

Ian Wallace of Third…

TXN

Texas Instruments

$120.00

0.56 (0.47%)

16:53
01/23/18
01/23
16:53
01/23/18
16:53
Hot Stocks
Texas Instruments says communications equipment market 'choppy' »

Says economy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

FB

Facebook

$189.35

3.98 (2.15%)

16:50
01/23/18
01/23
16:50
01/23/18
16:50
Hot Stocks
Facebook acquires mobile ID authentication startup Confirm.io »

Confirm.io announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

ASB

Associated Banc-Corp

$25.90

-0.15 (-0.58%)

, BKMU

BankMutual

$10.85

-0.1 (-0.91%)

16:46
01/23/18
01/23
16:46
01/23/18
16:46
Hot Stocks
Associated receives regulatory approvals to acquire BankMutual »

Associated Banc-Corp…

ASB

Associated Banc-Corp

$25.90

-0.15 (-0.58%)

BKMU

BankMutual

$10.85

-0.1 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

DKL

Delek Logistics

$32.80

0.5 (1.55%)

16:46
01/23/18
01/23
16:46
01/23/18
16:46
Hot Stocks
Delek Logistics raises quarterly dividend by 1.4% to 72.5c »

Delek Logistics Partner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

NTIP

Network-1 Technologies

$2.60

0.1 (4.00%)

, GOOG

Alphabet

$1,169.97

14.16 (1.23%)

16:45
01/23/18
01/23
16:45
01/23/18
16:45
Hot Stocks
Network-1 Technologies receives favorable ruling from federal circuit court »

Network-1 Technologies…

NTIP

Network-1 Technologies

$2.60

0.1 (4.00%)

GOOG

Alphabet

$1,169.97

14.16 (1.23%)

GOOGL

Alphabet Class A

$1,176.17

12.01 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

SIGM

Sigma Designs

$7.00

0.025 (0.36%)

16:45
01/23/18
01/23
16:45
01/23/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Sigma Designs »

Sigma Designs trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$40.06

0.75 (1.91%)

16:44
01/23/18
01/23
16:44
01/23/18
16:44
Hot Stocks
U.S. Steel 'pleased' with Presidential tariffs on certain imports »

United States Steel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

UAL

United Continental

$77.97

1.1 (1.43%)

16:42
01/23/18
01/23
16:42
01/23/18
16:42
Hot Stocks
United Continental says 2017 a 'transition' year »

Says understands that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

AUO

AU Optronics

$4.69

0.03 (0.64%)

16:42
01/23/18
01/23
16:42
01/23/18
16:42
Upgrade
AU Optronics rating change  »

AU Optronics upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGII

Argo Group

$65.10

0.05 (0.08%)

16:41
01/23/18
01/23
16:41
01/23/18
16:41
Hot Stocks
Argo Group reports preliminary pre-tax catastrophe loss of $34M-$38M in Q4 »

Argo Group International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$20.25

0.83 (4.27%)

16:40
01/23/18
01/23
16:40
01/23/18
16:40
Hot Stocks
MacroGenics completes interim futility analysis of the Phase 3 SOPHIA trial »

MacroGenicsannounced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$15.59

1.33 (9.33%)

16:38
01/23/18
01/23
16:38
01/23/18
16:38
Upgrade
LG Display rating change  »

LG Display upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$26.75

-0.22 (-0.82%)

16:37
01/23/18
01/23
16:37
01/23/18
16:37
Syndicate
Breaking Syndicate news story on GDS Holdings »

GDS Holdings files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:36
01/23/18
01/23
16:36
01/23/18
16:36
General news
API crude inventories for week of January 19 »

API reports that crude…

NAVI

Navient

$13.44

-0.08 (-0.59%)

16:34
01/23/18
01/23
16:34
01/23/18
16:34
Earnings
Breaking Earnings news story on Navient »

Navient reports Q4 GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

FHN

First Horizon

$20.11

0.01 (0.05%)

16:34
01/23/18
01/23
16:34
01/23/18
16:34
Hot Stocks
First Horizon replaces share repurchase program »

The board of First…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FHN

First Horizon

$20.11

0.01 (0.05%)

16:33
01/23/18
01/23
16:33
01/23/18
16:33
Hot Stocks
First Horizon increases quarterly dividend 33% »

First Horizon National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$19.29

-0.02 (-0.10%)

16:32
01/23/18
01/23
16:32
01/23/18
16:32
Hot Stocks
SandRidge Energy: Not in best interests of holders to accept Ichan's proposal »

SandRidge Energy issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CQP

Cheniere Energy Partners

$31.30

0.41 (1.33%)

16:32
01/23/18
01/23
16:32
01/23/18
16:32
Hot Stocks
Cheniere Energy Partners raises dividend to 50c from 44c »

Cheniere Energy Partners,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

GORO

Gold Resource

$4.97

0.05 (1.02%)

16:32
01/23/18
01/23
16:32
01/23/18
16:32
Hot Stocks
Gold Resource to expand Arista Mine vein system »

Gold Resource announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

TRMK

Trustmark

$33.53

-0.03 (-0.09%)

16:31
01/23/18
01/23
16:31
01/23/18
16:31
Earnings
Trustmark reports Q4 adjusted EPS 48c, consensus 47c »

Gerard R. Host, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

16:30
01/23/18
01/23
16:30
01/23/18
16:30
Options
Preliminary option volume of 22.5M today »

Preliminary option volume…

SBBP

Strongbridge Biopharma

$8.70

0.25 (2.96%)

16:27
01/23/18
01/23
16:27
01/23/18
16:27
Syndicate
Strongbridge Biopharma files to sell 5M shares of common stock »

JMP Securities is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.